{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T15:55:35Z","timestamp":1764431735140,"version":"3.41.2"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":141,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institutes of Health Research","award":["12\/206\/52"],"award-info":[{"award-number":["12\/206\/52"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>STUDY QUESTION<\/jats:title>\n                  <jats:p>Does application of an unbiased method for analysis of magnetic resonance (MR) images reveal any effect on uterine or fibroid volume from treatment of heavy menstrual bleeding (HMB) with three 12-week courses of the selective progesterone receptor modulator ulipristal acetate (SPRM-UPA)?<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SUMMARY ANSWER<\/jats:title>\n                  <jats:p>Application of an unbiased method for analysis of MR images showed that treatment of HMB with SPRM-UPA was not associated with a significant reduction in the volume of the uterus or in the volume of uterine fibroids.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                  <jats:p>SPRM-UPA shows therapeutic efficacy for treating HMB. However, the mechanism of action (MoA) is not well understood and there have been mixed reports, using potentially biased methodology, regarding whether SPRM-UPA has an effect on the volume of the uterus and fibroids.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                  <jats:p>In a prospective clinical study (with no comparator), 19 women with HMB were treated over a period of 12\u2009months with SPRM-UPA and uterine and fibroid size were assessed with high resolution structural MRI and stereology.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                  <jats:p>A cohort of 19 women aged 38\u201352\u00a0years (8 with and 11 without fibroids) were treated with three 12-week courses of 5\u2009mg SPRM-UPA given daily, with four weeks off medication in-between treatment courses. Unbiased estimates of the volume of uterus and total volume of fibroids were obtained at baseline, and after 6 and 12\u2009months of treatment, by using the Cavalieri method of modern design-based stereology in combination with magnetic resonance imaging (MRI).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                  <jats:p>Bland\u2013Altman plots showed good intra-rater repeatability and good inter-rater reproducibility for measurement of the volume of both fibroids and the uterus. For the total patient cohort, two-way ANOVA did not show a significant reduction in the volume of the uterus after two or three treatment courses of SPRM-UPA (P\u2009=\u20090.51), which was also the case when the groups of women with and without fibroids were considered separately (P\u2009=\u20090.63). One-way ANOVA did not show a significant reduction in total fibroid volume in the eight patients with fibroids (P\u2009=\u20090.17).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                  <jats:p>The study has been performed in a relatively small cohort of women and simulations that have subsequently been performed using the acquired data have shown that for three time points and a group size of up to 50, with alpha (Type I Error) and beta (Type II Error) set to 95% significance and 80% power, respectively, at least 35 patients would need to be recruited in order for the null hypothesis (that there is no significant reduction in total fibroid volume) to be potentially rejected.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                  <jats:p>The imaging protocol that we have developed represents a generic paradigm for measuring the volume of the uterus and uterine fibroids that can be readily incorporated in future studies of medical treatments of HMB. In the present study, SPRM-UPA failed to produce a significant reduction in the volume of the uterus or the total volume of fibroids (which were present in approximately half of the patients) after either two or three 12-week courses of treatment. This finding represents a new insight in respect of the management of HMB using treatment strategies that target hormone-dependence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                  <jats:p>The UPA Versus Conventional Management of HMB (UCON) trial was funded by the EME Programme (Medical Research Council (MRC) and National Institutes of Health Research (NIHR)) (12\/206\/52). The views expressed in this publication are those of the authors and not necessarily those of the Medical Research Council, National Institute for Health Research, or Department of Health and Social Care.<\/jats:p>\n                  <jats:p>Medical Research Council (MRC) Centre grants to the Centre for Reproductive Health (CRH) (G1002033 and MR\/N022556\/1) are also gratefully acknowledged. H.C. has clinical research support for laboratory consumables and staff from Bayer AG and provides consultancy advice (All paid to Institution) for Bayer AG, PregLem SA, Gedeon Richter, Vifor Pharma UK Ltd, AbbVie Inc., and Myovant Sciences GmbH. H.C. has received royalties from UpToDate for an article on abnormal uterine bleeding. L.W. has received grant funding from Roche Diagnostics (Paid to Institution). All other authors have no conflicts to declare.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                  <jats:p>The study reported here is an embedded mechanism of action study (no comparator) within the UCON clinical trial (registration ISRCTN: 20426843).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/hropen\/hoad021","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T22:04:02Z","timestamp":1684793042000},"source":"Crossref","is-referenced-by-count":3,"title":["Measurement of changes in uterine and fibroid volume during treatment of heavy menstrual bleeding (HMB)"],"prefix":"10.1093","volume":"2023","author":[{"given":"K","family":"Yin","sequence":"first","affiliation":[{"name":"Edinburgh Imaging Facility QMRI, University of Edinburgh , Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Whitaker","sequence":"additional","affiliation":[{"name":"MRC Centre for Reproductive Health, University of Edinburgh , Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Hojo","sequence":"additional","affiliation":[{"name":"MRC Centre for Reproductive Health, University of Edinburgh , Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"McLenachan","sequence":"additional","affiliation":[{"name":"Royal Infirmary of Edinburgh, NHS Lothian , Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Walker","sequence":"additional","affiliation":[{"name":"Royal Infirmary of Edinburgh, NHS Lothian , Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"McKillop","sequence":"additional","affiliation":[{"name":"Royal Infirmary of Edinburgh, NHS Lothian , Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Stubbs","sequence":"additional","affiliation":[{"name":"Birmingham Clinical Trials Unit, University of Birmingham , Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Priest","sequence":"additional","affiliation":[{"name":"Birmingham Clinical Trials Unit, University of Birmingham , Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4767-530X","authenticated-orcid":false,"given":"M","family":"Cruz","sequence":"additional","affiliation":[{"name":"Departamento de Matem\u00e1ticas Estad\u00edstica y Computaci\u00f3n, University of Cantabria , Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5538-8653","authenticated-orcid":false,"given":"N","family":"Roberts","sequence":"additional","affiliation":[{"name":"Edinburgh Imaging Facility QMRI, University of Edinburgh , Edinburgh, UK"},{"name":"MRC Centre for Reproductive Health, University of Edinburgh , Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1913-4044","authenticated-orcid":false,"given":"H","family":"Critchley","sequence":"additional","affiliation":[{"name":"MRC Centre for Reproductive Health, University of Edinburgh , Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"key":"2023060802011198700_hoad021-B1","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1002\/jum.14573","article-title":"Influence of ulipristal acetate therapy on uterine fibroid-related symptoms and on uterine and fibroid volumes and vascularity indices assessed by ultrasound","volume":"37","author":"Baggio","year":"2018","journal-title":"J Ultrasound Med"},{"key":"2023060802011198700_hoad021-B2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1067\/mob.2003.99","article-title":"High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence","volume":"188","author":"Baird","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"2023060802011198700_hoad021-B3","doi-asserted-by":"crossref","first-page":"402.e1","DOI":"10.1016\/j.ajog.2020.02.016","article-title":"Uterine fibroid incidence and growth in an ultrasound-based, prospective study of young African Americans","volume":"223","author":"Baird","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"2023060802011198700_hoad021-B4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.7863\/jum.2002.21.3.237","article-title":"The added value of transvaginal sonohysterography over transvaginal sonography alone in women with known or suspected leiomyoma","volume":"21","author":"Becker","year":"2002","journal-title":"J Ultrasound Med"},{"key":"2023060802011198700_hoad021-B5","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMra1209993","article-title":"Uterine fibroids","volume":"369","author":"Bulun","year":"2013","journal-title":"N Engl J Med"},{"key":"2023060802011198700_hoad021-B6","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/jmri.24717","article-title":"MR system operator: recommended minimum requirements for performing MRI in human subjects in a research setting","volume":"41","author":"Calamante","year":"2015","journal-title":"J Magn Reson Imaging"},{"key":"2023060802011198700_hoad021-B7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0029-7844(94)00298-R","article-title":"Transabdominal sonohysterography, transvaginal sonography, and hysteroscopy in the evaluation of submucous myomas","volume":"85","author":"Cicinelli","year":"1995","journal-title":"Obstet Gynecol"},{"key":"2023060802011198700_hoad021-B8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/ajcp\/94.4.435","article-title":"The frequency of uterine leiomyomas","volume":"94","author":"Cramer","year":"1990","journal-title":"Am J Clin Pathol"},{"key":"2023060802011198700_hoad021-B9","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ajog.2020.06.004","article-title":"Menstruation: science and society","volume":"223","author":"Critchley","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"2023060802011198700_hoad021-B10","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1152\/physrev.00031.2019","article-title":"Physiology of the endometrium and regulation of menstruation","volume":"100","author":"Critchley","year":"2020","journal-title":"Physiol Rev"},{"key":"2023060802011198700_hoad021-B11","first-page":"3","article-title":"Natural history of uterine polyps and leiomyomata","volume":"100","author":"DeWaay","year":"2002","journal-title":"Obstet Gynecol"},{"key":"2023060802011198700_hoad021-B12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.rbmo.2018.04.040","article-title":"Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review","volume":"37","author":"Donnez","year":"2018","journal-title":"Reprod Biomed Online"},{"key":"2023060802011198700_hoad021-B13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.fertnstert.2015.09.032","article-title":"Long-term medical management of uterine fibroids with ulipristal acetate","volume":"105","author":"Donnez","year":"2016","journal-title":"Fertil Steril"},{"key":"2023060802011198700_hoad021-B14","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"Ulipristal acetate versus placebo for fibroid treatment before surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"key":"2023060802011198700_hoad021-B15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"Ulipristal acetate versus leuprolide acetate for uterine fibroids","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"key":"2023060802011198700_hoad021-B16","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","article-title":"Long-term treatment of uterine fibroids with ulipristal acetate","volume":"101","author":"Donnez","year":"2014","journal-title":"Fertil Steril"},{"key":"2023060802011198700_hoad021-B17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0015-0282(01)01900-8","article-title":"Evaluation of the uterine cavity with magnetic resonance imaging, transvaginal sonography, hysterosonographic examination, and diagnostic hysteroscopy","volume":"76","author":"Dueholm","year":"2001","journal-title":"Fertil Steril"},{"key":"2023060802011198700_hoad021-B18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejogrb.2016.08.021","article-title":"Three-month treatment with ulipristal acetate prior to laparoscopic myomectomy of large uterine myomas: a retrospective study","volume":"205","author":"Ferrero","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2023060802011198700_hoad021-B19","doi-asserted-by":"crossref","first-page":"e024260","DOI":"10.1136\/bmjopen-2018-024260","article-title":"Factors associated with receiving surgical treatment for menorrhagia in England and Wales: findings from a cohort study of the National Heavy Menstrual Bleeding Audit","volume":"9","author":"Geary","year":"2019","journal-title":"BMJ Open"},{"key":"2023060802011198700_hoad021-B20","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/diagnostics10050334","article-title":"Reporting standards for a Bland-Altman agreement analysis: a review of methodological reviews","volume":"10","author":"Gerke","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"2023060802011198700_hoad021-B21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1046\/j.1365-2818.1999.00457.x","article-title":"The efficiency of systematic sampling in stereology\u2014reconsidered","volume":"193","author":"Gundersen","year":"1999","journal-title":"J Microsc"},{"key":"2023060802011198700_hoad021-B22","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/humrep\/dez015","article-title":"Variations in reproductive events across life: a pooled analysis of data from 505 147 women across 10 countries","volume":"34","author":"Inter Lace Study Team","year":"2019","journal-title":"Hum Reprod"},{"key":"2023060802011198700_hoad021-B23","doi-asserted-by":"crossref","first-page":"e0157375","DOI":"10.1371\/journal.pone.0157375","article-title":"A validated normative model for human uterine volume from birth to age 40 years","volume":"11","author":"Kelsey","year":"2016","journal-title":"PLoS One"},{"volume-title":"R Bloggers","year":"2012","author":"Kerns","key":"2023060802011198700_hoad021-B24"},{"volume-title":"Three Lectures on Systematic Geometric Sampling. Memoirs 13","year":"1997","author":"Ki\u00eau","key":"2023060802011198700_hoad021-B25"},{"key":"2023060802011198700_hoad021-B26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0378-3758(98)00193-1","article-title":"Precision of systematic sampling and transitive methods","volume":"77","author":"Ki\u00eau","year":"1999","journal-title":"J Stat Plan Inference"},{"key":"2023060802011198700_hoad021-B27","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/AOG.0b013e3181705d0e","article-title":"CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial","volume":"111","author":"Levens","year":"2008","journal-title":"Obstet Gynecol"},{"key":"2023060802011198700_hoad021-B28","first-page":"212","article-title":"The theory of regionalised variables and its applications","volume":"5","author":"Matheron","year":"1971","journal-title":"Les Cahiers Du Centre de Morphologie Mathematique"},{"key":"2023060802011198700_hoad021-B29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/whe.15.100","article-title":"Medical management of heavy menstrual bleeding","volume":"12","author":"Maybin","year":"2016","journal-title":"Womens Health (Lond)"},{"key":"2023060802011198700_hoad021-B30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijgo.2010.11.011","article-title":"FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age","volume":"113","author":"Munro","year":"2011","journal-title":"Int J Gynaecol Obstet"},{"key":"2023060802011198700_hoad021-B31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ijgo.12666","article-title":"The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions","volume":"143","author":"Munro","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"key":"2023060802011198700_hoad021-B32","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00129-017-4124-1","article-title":"Advantages of later motherhood","volume":"50","author":"Myrskyla","year":"2017","journal-title":"Gynakologe"},{"key":"2023060802011198700_hoad021-B33","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.rbmo.2019.07.028","article-title":"Predictors of uterine fibroid volume reduction under ulipristal acetate: a prospective MRI study","volume":"39","author":"Netter","year":"2019","journal-title":"Reprod Biomed Online"},{"volume-title":"NG88: Heavy Menstrual Bleeding: Assessment and Management","year":"2018","author":"NICE","key":"2023060802011198700_hoad021-B34"},{"key":"2023060802011198700_hoad021-B35","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.fertnstert.2010.09.059","article-title":"Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study","volume":"95","author":"Nieman","year":"2011","journal-title":"Fertil Steril"},{"key":"2023060802011198700_hoad021-B36","doi-asserted-by":"crossref","first-page":"19887","DOI":"10.1073\/pnas.0808188105","article-title":"Growth of uterine leiomyomata among premenopausal black and white women","volume":"105","author":"Peddada","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"year":"1998","author":"Puddephat","key":"2023060802011198700_hoad021-B37"},{"volume-title":"R: A Language and Environment for Statistical Computing","year":"2018","author":"R Core Team","key":"2023060802011198700_hoad021-B38"},{"volume-title":"National Heavy Menstrual Bleeding Audit \u2013 Final Report","year":"2014","author":"RCOG","key":"2023060802011198700_hoad021-B39"},{"key":"2023060802011198700_hoad021-B40","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1259\/bjr.73.871.11089458","article-title":"The benefit of stereology for quantitative radiology","volume":"73","author":"Roberts","year":"2000","journal-title":"Br J Radiol"},{"key":"2023060802011198700_hoad021-B41","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/bmj.293.6543.359","article-title":"Risk factors for uterine fibroids: reduced risk associated with oral contraceptives","volume":"293","author":"Ross","year":"1986","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2023060802011198700_hoad021-B42","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1056\/NEJMoa1904351","article-title":"Elagolix for heavy menstrual bleeding in women with uterine fibroids","volume":"382","author":"Schlaff","year":"2020","journal-title":"N Engl J Med"},{"key":"2023060802011198700_hoad021-B43","first-page":"359","article-title":"An epidemiological survey of symptoms of menstrual loss in the community","volume":"54","author":"Shapley","year":"2004","journal-title":"Br J Gen Pract"},{"key":"2023060802011198700_hoad021-B44","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0015-0282(99)00532-4","article-title":"Diagnostic accuracy of sonohysterography, transvaginal sonography, and hysterosalpingography in patients with uterine cavity diseases","volume":"73","author":"Soares","year":"2000","journal-title":"Fertil Steril"},{"key":"2023060802011198700_hoad021-B45","first-page":"35","article-title":"Evaluation and management of abnormal uterine bleeding in premenopausal women","volume":"85","author":"Sweet","year":"2012","journal-title":"Am Fam Physician"},{"key":"2023060802011198700_hoad021-B46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1933719114553451","article-title":"Unbiased and efficient estimation of the volume of the fibroid uterus using the Cavalieri method and magnetic resonance imaging","volume":"22","author":"Thrippleton","year":"2015","journal-title":"Reprod Sci"},{"key":"2023060802011198700_hoad021-B47","first-page":"321","article-title":"Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence","volume":"7","author":"Trefoux Bourdet","year":"2015","journal-title":"Int J Womens Health"},{"key":"2023060802011198700_hoad021-B48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7863\/jum.1998.17.1.17","article-title":"Clinical predictors in the natural history of uterine leiomyoma: preliminary study","volume":"17","author":"Tsuda","year":"1998","journal-title":"J Ultrasound Med"},{"key":"2023060802011198700_hoad021-B49","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/14728222.2016.1180368","article-title":"Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies","volume":"20","author":"Wagenfeld","year":"2016","journal-title":"Expert Opin Ther Targets"},{"key":"2023060802011198700_hoad021-B50","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bpobgyn.2015.11.012","article-title":"Abnormal uterine bleeding","volume":"34","author":"Whitaker","year":"2016","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"2023060802011198700_hoad021-B52","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/01443615.2017.1405926","article-title":"Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital","volume":"38","author":"Woodhead","year":"2018","journal-title":"J Obstet Gynaecol"},{"key":"2023060802011198700_hoad021-B53","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejogrb.2018.03.026","article-title":"Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate","volume":"224","author":"Yun","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"}],"container-title":["Human Reproduction Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/hropen\/advance-article-pdf\/doi\/10.1093\/hropen\/hoad021\/50418349\/hoad021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/hropen\/article-pdf\/2023\/3\/hoad021\/50536598\/hoad021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/hropen\/article-pdf\/2023\/3\/hoad021\/50536598\/hoad021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T02:01:56Z","timestamp":1686189716000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/hropen\/article\/doi\/10.1093\/hropen\/hoad021\/7175424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/hropen\/hoad021","relation":{},"ISSN":["2399-3529"],"issn-type":[{"type":"electronic","value":"2399-3529"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2023,1,1]]},"article-number":"hoad021"}}